The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular edema

被引:12
|
作者
Cicinelli, Maria Vittoria [1 ,2 ]
Rosenblatt, Amir [3 ,4 ]
Grosso, Domenico [2 ]
Zollet, Piero [2 ]
Capone, Luigi [2 ]
Rabiolo, Alessandro [2 ,5 ]
Lattanzio, Rosangela [2 ]
Loewenstein, Anat [3 ,4 ]
Bandello, Francesco [1 ,2 ]
机构
[1] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy
[2] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy
[3] Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[5] Gloucestershire Hosp NHS Fdn Trust, Dept Ophthalmol, Cheltenham, Glos, England
关键词
VITREOUS INSERTS; MANAGEMENT; RANIBIZUMAB; EFFICACY; BENEFIT; RETINA; 3-YEAR; SAFETY;
D O I
10.1038/s41433-020-01373-1
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background/Objectives To investigate if the visual and anatomic response to the first dexamethasone implant (DEX) predicts the 12-month clinical outcome after shifting to fluocinolone acetonide (FAc) implant in patients with diabetic macular oedema (DMO). Methods Retrospective cohort study including pseudophakic patients with previously treated DMO, undergone one or more DEX injections before FAc. Functional and morphologic response to DEX was defined based on the best-corrected visual acuity (BCVA) and central macular thickness (CMT) changes after the first DEX, respectively. Steroid-response was defined as intraocular pressure (IOP) elevation >= 5 mmHg or IOP > 21 mmHg after any previous DEX exposure. Pairwise comparisons for BCVA, CMT, and IOP after FAc were performed with linear mixed models and a repeated-measure design. Results Forty-four eyes of 33 patients were included. Patients were shifted to FAc after a mean +/- standard deviation of 4.6 +/- 3.2 DEX injections. Overall, BCVA and CMT improved during the first 12 months after switching to FAc (p = 0.04 and p < 0.001, respectively). Only eyes with a good morphologic response to DEX had a significant CMT reduction after FAc (p < 0.001), while no significant relationship was found between BCVA improvement after DEX and after FAc. IOP elevation occurred in 9 eyes (20%) following DEX implant. These eyes carried a 20-fold increased risk of having an IOP rise after FAc (p < 0.001), with a non-linear relationship between the IOP increase after DEX and the one after FAc. Conclusion The response to previous DEX may anticipate the morphologic response to subsequent FAc. Eyes with steroid-induced IOP elevation after DEX are at a high risk of IOP increase after FAc. The visual response after FAc was not associated with the visual response to previous steroids, indicating that FAc may have a role also in patients refractory to DEX implant.
引用
收藏
页码:3232 / 3242
页数:11
相关论文
共 50 条
  • [41] REPEATED INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR DIABETIC MACULAR EDEMA
    Bendello, F.
    Scaramuzzi, M.
    Lattanzio, R.
    Iuliano, L.
    Sacconi, R.
    Preziosa, C.
    Querques, G.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2014, 24 (03) : 466 - 466
  • [42] Dexamethasone intravitreal implant for diabetic macular edema in a pregnant patient
    Romi Yoo
    Hyung Chan Kim
    Hyewon Chung
    International Journal of Ophthalmology, 2016, (10) : 1524 - 1527
  • [43] Intravitreal Dexamethasone Implant in Patients with Persistent Diabetic Macular Edema
    Zucchiatti, Ilaria
    Lattanzio, Rosangela
    Querques, Giuseppe
    Querques, Lea
    Del Turco, Claudia
    Cascavilla, Maria Lucia
    Bandello, Francesco
    OPHTHALMOLOGICA, 2012, 228 (02) : 117 - 122
  • [44] Dexamethasone Intravitreal Implant for Diabetic Macular Edema During Pregnancy
    Concillado, Michael
    Lund-Andersen, Henrik
    Mathiesen, Elisabeth R.
    Larsen, Michael
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 165 : 7 - 15
  • [45] Early Response to Intravitreal Dexamethasone Implant Therapy in Diabetic Macular Edema May Predict Visual Outcome
    Al-Khersan, Hasenin
    Hariprasad, Seenu M.
    Chhablani, Jay
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2017, 184 : 121 - 128
  • [46] Early Response to Intravitreal Dexamethasone Implant Therapy in Diabetic Macular Edema May Predict Visual Outcome
    Calugaru, Dan
    Calugaru, Mihai
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2018, 186 : 164 - 165
  • [47] One-year Outcome of Intravitreal Dexamethasone Implant for Diabetic Macular Edema Patients
    Park, No Hae
    Kwak, Hyun Duck
    Yoon, Chang Ki
    Lee, Ji Eun
    Sagong, Min
    Lee, Sang Joon
    Lee, Joo Eun
    Kim, Kun Hyung
    Kim, Hyun Woong
    JOURNAL OF THE KOREAN OPHTHALMOLOGICAL SOCIETY, 2019, 60 (02): : 135 - 143
  • [48] Intravitreal fluocinolone acetonide implant for chronic postoperative cystoid macular edema - two years results
    Chronopoulos, Argyrios
    Chronopoulos, Panagiotis
    Hattenbach, L. O.
    Ashurov, Agharza
    Schutz, James S.
    Pfeiffer, Norbert
    Korb, Christina
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2023, 33 (02) : 1054 - 1060
  • [49] Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 μg intravitreal implant for diabetic macular edema
    Currie, Craig J.
    Holden, Sarah E.
    Owens, David R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 : 33 - 43
  • [50] Evaluation of the clinical effectiveness in routine practice of fluocinolone acetonide 190 μg intravitreal implant in people with diabetic macular edema
    Holden, Sarah E.
    Currie, Craig J.
    Owens, David R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 : 5 - 17